Diligence memo · auto-generated · as of July 2, 2026
Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Asterias Biotherapeutics, Inc. operates in Biotechnology, based in MENLO PARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Asterias Biotherapeutics, Inc. has raised $17M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2014-06-16.
Most recent recorded round closed around 2015-02-09.
Valuation (modeled)modeled
Provath models Asterias Biotherapeutics, Inc. at approximately $145M (range $4.4M–$786M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 11.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 65% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.